Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials

INTRODUCTION: Dalbavancin is a long-acting, bactericidal, lipoglycopeptide antibiotic approved by the US Food and Drug Administration and the European Medicines Agency for treatment of acute bacterial skin and skin structure infections in adults, with potent activity against Gram-positive pathogens,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, Pedro L., Rappo, Urania, Akinapelli, Karthik, McGregor, Jennifer S., Puttagunta, Sailaja, Dunne, Michael W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847487/
https://www.ncbi.nlm.nih.gov/pubmed/34905144
http://dx.doi.org/10.1007/s40121-021-00568-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847487/
https://www.ncbi.nlm.nih.gov/pubmed/34905144
http://dx.doi.org/10.1007/s40121-021-00568-7

Ejemplares similares